The median for patients with unmethylated glioblastoma treated with radiotherapy and temozolomide is 14.11 months.
Patients with unmethylated glioblastoma have a median of 4.99 months when treated with radiotherapy and temozolomide.
In contrast, patients with methylated glioblastoma have a median overall survival of 24.59 months and a median progression-free survival of 9.51 months.
Data on overall survival and progression-free survival for unmethylated patients treated with radiotherapy alone is limited.
This analysis indicates substantial differences in survival outcomes between patients with methylated and unmethylated glioblastoma treated with the same regimen.
Simplified
BACKGROUND: The current standard of care for the management of patients with newly diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). While it is well established that TMZ has better efficacy in patients withpromoter methylation, it remains an area of debate whether TMZ should be omitted when treating GBM patients with unmethylated. MGMT MGMT
METHODS: We conducted a systematic review and meta-analysis to provide separate estimates of median (OS) and (PFS) for patients with methylated and unmethylated GBM treated with RT with or without TMZ. We searched multiple databases from inception to January 13, 2020.
RESULTS: The median OS for patients with unmethylated GBM treated with RT/TMZ pooled from 5 phase III studies (= 655) was 14.11 months (95% confidence interval [CI], 13.18-15.04) with a median PFS of 4.99 months (95% CI, 4.25-5.72). In contrast, the median OS for patients with methylated GBM pooled from 6 studies (= 753) was 24.59 months (95% CI, 22.19-26.99) with a median PFS pooled from 7 studies (= 805) of 9.51 months (95% CI, 7.41-11.61). There is a paucity of prospective data pertaining to OS/PFS in unmethylated patients treated with RT only and therefore a direct comparison was not possible. N N N
CONCLUSIONS: This meta-analysis provides estimates of survival for patients withmethylated or unmethylated GBM treated with RT/TMZ. Further research is needed to delineate whether TMZ should be withheld for patients with unmethylated GBM outside of the setting of clinical trials. MGMT
Key numbers
14.11 months
Median for unmethylated GBM
Pooled from 5 phase III studies involving 655 patients.
24.59 months
Median for methylated GBM
Pooled from 6 studies involving 753 patients.
4.99 months
Median for unmethylated GBM
Pooled from 5 phase III studies involving 655 patients.
Full Text
We can’t show the full text here under this license.
